KP Tissue posts presentation for June 15 annual shareholder meeting

  • KP Tissue released its annual shareholder meeting presentation, with votes set for director elections and auditor re-appointment.
  • 2025 revenue totaled CAD 2.2 billion; adjusted EBITDA reached CAD 318.2 million.
  • Q1 2026 revenue was CAD 544.6 million; adjusted EBITDA was CAD 86.9 million; net income was CAD 19.8 million.
  • Net debt was CAD 962.2 million in Q1 2026; net leverage was 2.9x based on LTM adjusted EBITDA of CAD 329.3 million.
  • Strategy update highlighted preparation for a new TAD tissue plant in the western US; Memphis converting-line ramp cited as a near-term focus.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KP Tissue Inc. published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.